
Contrary to earlier findings, inhaled nitric oxide (NO) therapy for lung immaturity in premature infants does not reduce an infant's risk of death or further lung problems, according to a study by the National Institute of Child Health and Human Development (NICHD) of the National Institutes of Health that appeared in the July 7 issue of the New England Journal of Medicine. "Premature infants weighing less than 1,500 g should not receive inhaled NO therapy unless they are part of a research study," said NICHD Director Duane Alexander, MD.
